Video Experimental Relacionado
Updated: May 30, 2026
08:30
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
En busca de nuevos objetivos terapéuticos y estrategias para la insuficiencia cardíaca: avances recientes en la
1King's College London British Heart Foundation Centre of Excellence, London, UK. ajay.shah@kcl.ac.uk
Lancet (London, England)
|August 23, 2011
Resumen
La insuficiencia cardíaca crónica (ICC) es impulsada por la remodelación cardíaca. Esta revisión explora los mecanismos moleculares y los objetivos terapéuticos para la CHF, con el objetivo de mejorar los resultados de los pacientes y reducir las cargas sanitarias.
Área de la Ciencia:
- Cardiología Cardiología.
- Biología Molecular Biología Molecular
- Fisiopatología Fisiopatología.
Sus antecedentes:
- La insuficiencia cardíaca crónica (ICC) presenta un desafío sanitario significativo a pesar de los avances terapéuticos.
- La remodelación cardíaca, una respuesta a la enfermedad crónica, es el principal impulsor de la progresión de la insuficiencia cardíaca congestiva.
Objetivo del estudio:
- Revisar los mecanismos moleculares y celulares recientes que subyacen a la remodelación cardíaca en la insuficiencia cardíaca congestiva.
- Para identificar posibles objetivos terapéuticos para la intervención de CHF.
Principales métodos:
- Revisión de la literatura de los mecanismos moleculares y celulares en la remodelación cardíaca.
- Concéntrese en las vías que regulan la hipertrofia de los miocitos, la homeostasis del calcio, la energía y la supervivencia celular.
- Examen de la matriz extracelular y las contribuciones vasculares a la remodelación.
Principales resultados:
- Identificó las principales vías moleculares involucradas en la remodelación cardíaca.
- Destacó posibles objetivos terapéuticos dentro de estas vías.
- Se discutieron las limitaciones de los enfoques actuales de descubrimiento de objetivos.
Conclusiones:
- La comprensión de los mecanismos de remodelación cardíaca es crucial para el desarrollo de nuevas terapias de CHF.
- Se necesitan nuevas vías de investigación para acelerar los descubrimientos clínicamente relevantes para el tratamiento de la CHF.
Videos de Conceptos Relacionados
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...